Sharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility Upgrades
MWN-AI** Summary
Sharps Technology, Inc. (Nasdaq: STSS), a leader in medical device and pharmaceutical packaging, has announced significant advancements in its operations, including the execution of shipments under its $50 million SoloGard supply agreement. This multi-year contract with a prominent U.S. healthcare provider is centered around the supply of SoloGard smart safety syringes, designed for IV flushing solutions. As part of this initiative, Sharps has commenced the second shipment of syringes while simultaneously enhancing its manufacturing capabilities to accommodate expected production demands.
The company’s strategic upgrades involve the deployment of next-generation injection molding systems, which are set to increase manufacturing capacity and streamline cleanroom operations. Additionally, new machinery is being implemented to achieve over ten times the energy efficiency of previous systems, contributing to cost reductions and promoting sustainable production practices. Enhancements to cleanroom environments and control systems also aim to ensure higher product quality and regulatory compliance.
CEO Robert Hayes emphasized the significance of these developments, noting that fulfilling the second shipment marks a pivotal moment in the company's transition to revenue-generating operations. Sharps is executing a $400,000 purchase order as part of its broader five-year agreement, which includes supplying up to 500 million SoloGard syringes known for their ultra-low waste design and advanced safety features.
These upgrades not only bolster Sharps’ capabilities to fulfill major contracts but also position the company as a key innovation-driven partner within the healthcare sector. With a focus on scaling operations and enhancing efficiency, Sharps Technology is geared toward sustaining growth and advancing its presence in the market.
MWN-AI** Analysis
Sharps Technology, Inc. (NASDAQ: STSS) is positioned at a critical juncture following its recent updates on the SoloGard supply agreement and manufacturing facility enhancements. The company is set to benefit significantly from its multi-year contract with a major U.S. healthcare partner, particularly as it fulfills the second shipment of SoloGard syringes, part of a transformative $50 million agreement.
The strategic manufacturing upgrades Sharps has embarked upon are not merely reactive but proactive measures aimed at scalability and efficiency. By deploying next-generation injection molding systems and improving cleanroom environments, Sharps is gearing up to meet projected demand in the latter half of 2025. These advancements not only enhance production capacity but also reinforce Sharps' commitment to sustainability and cost efficiency, crucial factors in the competitive healthcare market.
Investors should pay close attention to the implications of these developments. The company’s pivot toward revenue-generating operations, evidenced by the significant $400,000 purchase order and the broader goal of supplying 500 million syringes, signals a strong move towards establishing stable cash flows. As Sharps capitalizes on its patented safety syringe technology, including FDA-and WHO-approved products with ultra-low waste designs, it positions itself as a leader in innovative medical solutions.
Given the growing demand for safety syringes, particularly in light of global health initiatives, this agreement places Sharps at an advantageous point in the market. Analysts may consider that the company’s focus on advanced manufacturing capabilities could enhance profitability, positioning it as a potentially attractive investment opportunity.
However, investors should remain cognizant of risks associated with forward-looking statements. Factors such as market competition, regulatory changes, and execution risks could impact future performance. Therefore, while the outlook is promising, a balanced approach with a focus on ongoing developments will be crucial for assessing Sharps' long-term viability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Second commercial delivery underway as part of multi-year contract with leading U.S. healthcare partner
Strategic manufacturing upgrades drive scalability, efficiency, and increases capacity to support production growth
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced an update on the execution of its first shipments under the previously announced $50 million SoloGard sales agreement, alongside a series of advanced manufacturing upgrades.
Sharps has initiated the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a U.S.-based leader in IV flushing solutions. In preparation for increasing production through the second half of the year, SoloGard manufacturing will be supported by newly installed molding and automation systems - investments that enable Sharps to meet anticipated demand in the second half of 2025 under the sales agreement.
As part of a phased manufacturing upgrade strategy, Sharps is implementing the following initiatives:
- Preparation and fulfillment of the second shipment under the multi-year agreement, continuing to meet customer demand
- Deployment of next-generation injection molding systems to expand manufacturing capacity and streamline cleanroom operations
- Installation of new machinery delivering over 10x energy efficiency compared to prior systems, reducing costs and advancing sustainable production
- Facility upgrades to cleanroom environments and control systems, enhancing product quality and regulatory compliance
- Integration of new ancillary systems to increase throughput and optimize molding and assembly workflows
Sharps is currently executing a $400,000 purchase order, announced June 4, 2025, as part of a broader five-year agreement to supply up to 500 million SoloGard syringes, marking the company’s transition into revenue-generating commercial operations. The contract includes customized 10mL SoloGard smart safety syringes - FDA- and WHO-approved devices that feature ultra-low waste design, standard luer lock compatibility, and re-use prevention technology.
Robert Hayes, CEO of Sharps Technology, commented: “Fulfilling this second shipment marks a significant milestone as we move into commercial execution under the $50 million SoloGard agreement. Over the past several months, we’ve made strategic investments in advanced molding systems, automation, and cleanroom infrastructure. These are transformational upgrades that expand capacity while improving energy efficiency, consistency, and our overall cost structure. These enhancements are central to our long-term strategy, allowing Sharps to fulfill major contracts, scale recurring revenue, and position the Company as an innovation-driven manufacturing partner to the healthcare industry.”
About Sharps Technology:
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit www.sharpstechnology.com .
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Contact:
Holdsworth Partners
Adam Holdsworth
Phone: 917-497-9287
Email: IR@sharpstechnology.com
FAQ**
How does the second shipment under the $50 million contract with your healthcare partner impact the overall financial outlook for Sharps Technology Inc. Warrant STSSW in the coming quarters?
Can you elaborate on how the recent manufacturing upgrades will affect the production efficiency and scalability of Sharps Technology Inc. Warrant STSSW's operations moving forward?
What measures is Sharps Technology Inc. Warrant STSSW taking to ensure compliance with FDA and WHO standards as production ramps up under the multi-year agreement?
With the significant investment in new machinery, how will these advancements influence the competitive positioning of Sharps Technology Inc. Warrant STSSW in the medical device market?
**MWN-AI FAQ is based on asking OpenAI questions about Sharps Technology Inc. Warrant (NASDAQ: STSSW).
NASDAQ: STSSW
STSSW Trading
-4.44% G/L:
$0.0215 Last:
6,056 Volume:
$0.0215 Open:
